Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer carbonate in pediatric hyperphosphatemia with chronic kidney disease
2011-002329-23Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sevelamer carbonate in hyperphosphatemia and chronic kidney disease (CKD) (3 arms), sponsored by Sanofi. Primary endpoint: Change from baseline to Visit 3 in serum phosphorus. Started Mar 2013; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2011-002329-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002329-23.